François Quenet is an expert in Surgery at Institut du Cancer de Montpellier (France). François Quenet has authored 179 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 1 of them ongoing. SLR score: 538 (community average: 125). How the SLR is computed.

LeadR Profile

François Quenet Institut du Cancer de Montpellier France
538 ScienceLeadR Reputation 538
Network Map

Surgery

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2011 - 2026

Source: PubMed

University of Montpellier

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 179

Citations

Citations: 8 931 1st author: 15 Last author: 20 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial.
PMID 42018958 — safety, drug therapy, oxaliplatin, liver, neoplasm metastasis, medical oncology, chemotherapy
J Clin Oncol Top journal20260
Segmental Atrophy of the Liver: An Increasingly Recognized Pseudotumor With Distinct Clinicopathologic and Imaging Features.
PMID 41957927 — vascular system injuries, hepatic veno-occlusive disease, myofibroblasts, atrophy, neoplasms, liver, pathology, surgical, thrombosis, wounds and injuries
Am J Surg Pathol20260
Feasibility and safety profile of high-dose oxaliplatin-based PIPAC (120mg/m2) in the treatment of advanced peritoneal metastatic disease: MINOS real-life multicenter study.
PMID 41830675 — safety, pain, oxaliplatin, therapeutics, medical oncology, pressurized intraperitoneal aerosol chemotherapy
Eur J Surg Oncol20260
The PSOGI consensus on minimally-invasive surgery for peritoneal surface malignancy.
PMID 41777073 — minimally invasive surgical procedures, neoplasms, peritoneal neoplasms, general surgery
Br J Surg20260
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice.
PMID 40139833 — cells, growth, blood, neoplasms, colon, neutrophils, oxaliplatin, fluorouracil, immunotherapy, therapeutics
J Immunother Cancer20250

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 1

By phase:

N/A 6
Phase 3 4
Phase 2 2

By status:

Completed 8
Recruiting 3
Active not recruiting 1

By type:

Interventional 10
Observational 2

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 0
multicentric5to9 0
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
metastatic colorectal cancer
2023-504831-42-00 — neoplasms, drug therapy, liver, neoplasm metastasis, therapeutics, colorectal neoplasms, chemotherapy
Phase 3Recruiting2025

LeadR Networks

Main global connection map